文献速递临床生化临床免疫分子诊断

胸腔积液生化分析:过去、现在与未来

Pleural fluid biochemical analysis: the past, present and future.
PubMed 文献 · Clin Chem Lab Med · 2022-11-17

本文综述了胸腔积液生化分析的历史、现状与未来。回顾了Light标准及其修改版的历史,以及心衰、恶性胸腔积液、结核性胸腔积液和类肺炎性胸腔积液的生物标志物现状,并展望了机器学习、分子诊断和高通量技术的应用前景。

要点

  • 生化分析具有低成本、微创、观察者独立和周转时间短的优势。
  • Light标准及其修改版是胸腔积液鉴别诊断的历史基石。
  • 心衰、恶性、结核性和类肺炎性胸腔积液各有对应的生物标志物。

核心结论

  • 胸腔积液生化分析在诊断中具有优势,未来可结合机器学习、分子诊断和高通量技术发展。

研究设计与样本

  • 本文为综述,回顾了胸腔积液生化分析的过去、现在和未来。

主要发现

  • 生化分析具有低成本、微创、观察者独立和短周转时间的优势。
  • 回顾了Light标准及其修改版的历史。
  • 总结了心衰、恶性胸腔积液、结核性胸腔积液和类肺炎性胸腔积液的生物标志物现状。
  • 展望了机器学习、分子诊断和高通量技术在胸腔积液生化分析中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identifying the cause of pleural effusion is challenging for pulmonologists. Imaging, biopsy, microbiology and biochemical analyses are routinely used for diagnosing pleural effusion. Among these diagnostic tools, biochemical analyses are promising because they have the advantages of low cost, minimal invasiveness, observer independence and short turn-around time. Here, we reviewed the past, present and future of pleural fluid biochemical analysis. We reviewed the history of Light's criteria and its modifications and the current status of biomarkers for heart failure, malignant pleural effusion, tuberculosis pleural effusion and parapneumonic pleural effusion. In addition, we anticipate the future of pleural fluid biochemical analysis, including the utility of machine learning, molecular diagnosis and high-throughput technologies. Clinical Chemistry and Laboratory Medicine (CCLM) should address the topic of pleural fluid biochemical analysis in the future to promote specific knowledge in the laboratory professional community.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Zheng WQ, Hu ZD. Pleural fluid biochemical analysis: the past, present and future. Clin Chem Lab Med. 2022. PMID: 36383033. doi:10.1515/cclm-2022-0844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。